Core Viewpoint - Dyadic International, Inc. has received a funding award from CEPI to utilize its C1 platform for accelerating the development of protein-based vaccines, aiming to significantly reduce production time and costs [1][5][6] Group 1: Funding and Collaboration - CEPI is providing US$4.5 million to Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research on producing antigens using Dyadic's C1 filamentous fungus technology [2] - The partnership supports the 100 Days Mission, which aims to reduce vaccine development timelines to just over three months in response to pandemic threats [5][12] Group 2: Technology and Production Efficiency - Traditional mammalian cell methods for producing protein antigens can take four to six months due to the need for stable cell line creation, while the C1 fungus technology could reduce this to just 35 days [3] - The C1 fungus technology is expected to produce large quantities of proteins that can be easily scaled, requiring less complex and expensive biopharmaceutical facilities compared to mammalian cell cultures [4] Group 3: Strategic Goals and Future Directions - CEPI's funding will focus on producing a SARS-CoV-2 spike protein to compare the efficacy of antigens produced by C1 fungus versus traditional mammalian cells [6][7] - Successful outcomes from this project could lead to selecting antigens from other pathogens of interest to CEPI, further demonstrating reduced timelines for vaccine development [7]
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines